LU93138I2 - Glycoprotéine d'hyaluronidase soluble (shasegp), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant - Google Patents

Glycoprotéine d'hyaluronidase soluble (shasegp), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant Download PDF

Info

Publication number
LU93138I2
LU93138I2 LU93138C LU93138C LU93138I2 LU 93138 I2 LU93138 I2 LU 93138I2 LU 93138 C LU93138 C LU 93138C LU 93138 C LU93138 C LU 93138C LU 93138 I2 LU93138 I2 LU 93138I2
Authority
LU
Luxembourg
Prior art keywords
shasegp
neutral active
soluble
preparation
pharmaceutical compositions
Prior art date
Application number
LU93138C
Other languages
English (en)
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93138(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Halozyme Inc filed Critical Halozyme Inc
Publication of LU93138I2 publication Critical patent/LU93138I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
LU93138C 2003-03-05 2016-07-04 Glycoprotéine d'hyaluronidase soluble (shasegp), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant LU93138I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45236003P 2003-03-05 2003-03-05
EP04717941A EP1603541B2 (fr) 2003-03-05 2004-03-05 Glycoproteine hyaluronidase soluble (shasegp), procede de fabrication et compositions pharmaceutiques contenant ladite proteine
EP09012669.9A EP2177620B1 (fr) 2003-03-05 2004-03-05 Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant

Publications (1)

Publication Number Publication Date
LU93138I2 true LU93138I2 (fr) 2016-09-05

Family

ID=32962713

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92780C LU92780I2 (fr) 2003-03-05 2015-07-20 Trastuzumab et hyaluronidase humaine recombinante
LU93138C LU93138I2 (fr) 2003-03-05 2016-07-04 Glycoprotéine d'hyaluronidase soluble (shasegp), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92780C LU92780I2 (fr) 2003-03-05 2015-07-20 Trastuzumab et hyaluronidase humaine recombinante

Country Status (27)

Country Link
US (14) US7767429B2 (fr)
EP (7) EP2163643B1 (fr)
JP (3) JP4464395B2 (fr)
KR (4) KR20130135986A (fr)
CN (2) CN1942588B (fr)
AT (1) ATE448323T1 (fr)
AU (2) AU2004218354B2 (fr)
BR (1) BRPI0408116B1 (fr)
CA (1) CA2517145C (fr)
CY (6) CY1109750T1 (fr)
DE (1) DE602004024041D1 (fr)
DK (4) DK2177620T3 (fr)
EA (1) EA009383B1 (fr)
ES (4) ES2532399T3 (fr)
FR (1) FR16C0030I1 (fr)
HK (4) HK1086746A1 (fr)
HU (2) HUE027661T2 (fr)
IL (2) IL170300A (fr)
LU (2) LU92780I2 (fr)
MX (1) MXPA05009429A (fr)
NZ (1) NZ542873A (fr)
PL (4) PL1603541T5 (fr)
PT (3) PT2177620E (fr)
SG (2) SG2012041067A (fr)
SI (4) SI2177620T1 (fr)
WO (1) WO2004078140A2 (fr)
ZA (1) ZA200507978B (fr)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
EP1636248A4 (fr) 2002-12-16 2006-09-06 Halozyme Inc Glycoproteine de chondroitinase (chasegp) humaine, son procede de preparation et compositions pharmaceutiques comprenant ladite glycoproteine
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2517145C (fr) 2003-03-05 2017-08-01 Halozyme, Inc. Glycoproteine hyaluronidase soluble (shasegp), procede de fabrication et compositions pharmaceutiques contenant ladite proteine
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
CN102416020A (zh) * 2004-12-30 2012-04-18 建新公司 用于关节内粘弹性补充的方案
JP5396080B2 (ja) 2005-06-30 2014-01-22 アッヴィ・インコーポレイテッド ＩＬ−１２／ｐ４０結合蛋白質
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2500353A3 (fr) 2005-08-19 2012-10-10 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
NZ571758A (en) * 2006-03-31 2012-06-29 Quadra Logic Tech Inc A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye
RU2472807C2 (ru) 2006-09-08 2013-01-20 Эбботт Лэборетриз Интерлейкин-13-связывающие белки
JP5298021B2 (ja) 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
US20080160003A1 (en) * 2006-10-31 2008-07-03 University Of Delaware Fertility Enhancement Using Lipid Carriers and Bioactive Molecules
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2009037566A2 (fr) * 2007-06-19 2009-03-26 Uvarkina Tamara P Hyaluronidase et son procédé d'utilisation
CN101861135A (zh) * 2007-09-07 2010-10-13 Qlt栓塞输送公司 泪道植入物检测
US20090143436A1 (en) * 2007-11-06 2009-06-04 Weg Stuart L Anesthetic composition, formulation and method of use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
JP5650546B2 (ja) * 2008-03-06 2015-01-07 ハロザイム インコーポレイテッド 可溶性ヒアルロニダーゼの大規模生産
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
NZ588638A (en) * 2008-04-14 2012-09-28 Halozyme Inc Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR071698A1 (es) 2008-05-09 2010-07-07 Abbott Gmbh & Co Kg Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2011527579A (ja) 2008-07-08 2011-11-04 アボット・ラボラトリーズ プロスタグランジンｅ２結合タンパク質およびこの使用
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
TW201016233A (en) * 2008-07-15 2010-05-01 Genentech Inc Methods of treating autoimmune diseases using CD4 antibodies
EP2177227B1 (fr) * 2008-10-14 2013-03-20 Burgard, Gunter, Dr. med. Utilisation d'hyaluronidase pour la prévention ou le traitement de l'hypertension artérielle.
GB0819883D0 (en) 2008-10-29 2008-12-03 Azyme Res As Product and uses
WO2010077297A1 (fr) * 2008-12-09 2010-07-08 Halozyme, Inc. Polypeptides ph20 solubles étendus et leurs applications
AU2013202000B2 (en) * 2008-12-09 2015-07-30 Halozyme, Inc. Extended soluble PH20 polypeptides and uses thereof
US20100209558A1 (en) * 2009-02-19 2010-08-19 General Nutrition Corporation Dietary ingredient with enhanced bioavailability
JP5836807B2 (ja) 2009-03-05 2015-12-24 アッヴィ・インコーポレイテッド Ｉｌ−１７結合タンパク質
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
DE102009003291A1 (de) * 2009-05-20 2010-12-30 Henkel Ag & Co. Kgaa Kosmetische Zusammensetzung und Verformungsverfahren für keratinische Fasern
WO2010138918A1 (fr) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase comme adjuvant pour augmenter le volume d'injection et la dispersion de vésicules membranaires synthétiques de grand diamètre contenant un agent thérapeutique
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US20120100555A1 (en) * 2009-06-29 2012-04-26 Martin James Lear Synthesis And Use Of Fluorophore-Tagged Antimalarials
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
PE20121530A1 (es) 2009-09-01 2012-12-22 Abbvie Inc Inmunoglobulinas con dominio variable dual
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR112012005890B1 (pt) * 2009-09-17 2023-01-17 Takeda Pharmaceutical Company Limited Co-formulação estável de hialuronidase e imunoglobulina e métodos de utilização da mesma
JP2013507928A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201121568A (en) 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN102656190A (zh) 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
WO2011130377A2 (fr) 2010-04-15 2011-10-20 Abbott Laboratories Protéines de liaison à la bêta amyloïde
KR101848225B1 (ko) 2010-05-14 2018-04-12 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
WO2012006500A2 (fr) 2010-07-08 2012-01-12 Abbott Laboratories Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX348420B (es) 2010-07-20 2017-06-12 Halozyme Inc Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
WO2012018790A2 (fr) 2010-08-03 2012-02-09 Abbott Laboratories Immunoglobulines à double domaine variable et utilisations associées
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CA2810668A1 (fr) 2010-09-08 2012-03-15 Halozyme, Inc. Procedes d'evaluation et d'identification ou d'evolution de proteines therapeutiques conditionnellement actives
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US10610486B2 (en) 2010-10-28 2020-04-07 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
TWI603738B (zh) 2010-11-08 2017-11-01 建南德克公司 皮下投予抗－ｉｌ－６受體抗體
AU2011361720B2 (en) 2010-12-21 2017-04-27 Abbvie Inc. IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
EP2670434B1 (fr) * 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Traitement de tauopathies
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
BR112013032265A2 (pt) 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
EA033472B1 (ru) 2011-06-17 2019-10-31 Halozyme Inc Композиция для стабилизации гиалуронидазы и ее применение
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
CA2841970A1 (fr) 2011-07-13 2013-01-17 Abbvie Inc. Methodes et compositions pour le traitement de l'asthme a l'aide d'anticorps anti-il-13
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
EP2771361A1 (fr) 2011-10-24 2014-09-03 AbbVie Inc. Agents de liaison immunologique bispécifiques contre le tnf et l'il-17
RU2014120981A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
EP2771028A2 (fr) 2011-10-24 2014-09-03 Halozyme, Inc. Diagnostic compagnon pour le traitement avec un agent anti-hyaluronane et procédés d'utilisation dudit diagnostic
JP6336397B2 (ja) 2011-12-14 2018-06-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
US10118958B2 (en) 2011-12-14 2018-11-06 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2013102144A2 (fr) 2011-12-30 2013-07-04 Halozyme, Inc. Variants du polypeptide ph20, formulations en contenant et leurs utilisations
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
JP6271441B2 (ja) 2012-01-27 2018-01-31 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 神経突起変性に関連する疾患を診断および治療するための組成物および方法
WO2013151774A1 (fr) 2012-04-04 2013-10-10 Halozyme, Inc. Polythérapie par un agent anti-hyaluronane et un taxane ciblant une tumeur
CN104379741B (zh) 2012-04-23 2021-07-20 基因先端领域株式会社 抗人cd69抗体及其用于医疗目的的用途
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
WO2014062856A1 (fr) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxie et hyaluronane et leurs marqueurs pour le diagnostic et la surveillance de maladies et de pathologies, et méthodes associées
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
KR101454646B1 (ko) * 2012-11-05 2014-10-27 (주)한국비엠아이 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제
CN104937099B (zh) 2012-11-09 2018-03-30 基因先端领域株式会社 用于治疗癌症的抗adam28抗体
WO2014107745A1 (fr) 2013-01-07 2014-07-10 Halozyme, Inc. Métalloprotéases matricielles mutantes sensibles aux métaux et leurs utilisations
BR112015023348B1 (pt) 2013-03-14 2023-04-25 The University Of Massachusetts Composição oftálmica
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
TWI476203B (zh) 2013-03-18 2015-03-11 Ind Tech Res Inst 醣類的分離方法
WO2014165713A2 (fr) 2013-04-03 2014-10-09 Cedars-Sinai Medical Center Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase
JP6581572B2 (ja) 2013-06-07 2019-09-25 デューク ユニバーシティ 補体因子ｈ阻害薬
WO2014200018A1 (fr) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
BR112015033053A2 (pt) 2013-07-03 2018-03-20 Hope City método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3035903B1 (fr) 2013-08-20 2018-08-22 Anutra Medical, Inc. Système de remplissage de seringue et procédé associé
US9968623B2 (en) * 2013-08-29 2018-05-15 Lanny Leo Johnson Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
KR102435648B1 (ko) 2013-09-11 2022-08-25 이글 바이오로직스 인코퍼레이티드 점도저하제를 함유하는 액체 단백질 제형
EP3057992B1 (fr) 2013-10-15 2024-04-17 GeneFrontier Corporation Anticorps humain contre les espèces adamts de type agrécanase pour des agents thérapeutiques contre des maladies associées à l'agrécanase
WO2015057622A1 (fr) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
JP2016540761A (ja) 2013-12-02 2016-12-28 アッヴィ・インコーポレイテッド 変形性関節症を治療するための組成物及び方法
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015138337A1 (fr) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions et méthodes de traitement d'une polyarthrite rhumatoïde
IL295906A (en) 2014-03-21 2022-10-01 Abbvie Inc Antibodies against egfr and drug antibody conjugates
US10117886B2 (en) 2014-05-30 2018-11-06 Hao Cheng Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
WO2015191760A2 (fr) 2014-06-10 2015-12-17 Abbvie, Inc. Compositions et méthodes pour traiter la polyarthrite rhumatoïde
CN106714824A (zh) * 2014-07-16 2017-05-24 纽约大学 透明质酸酶用于治疗肌肉僵硬的用途
WO2016033555A1 (fr) 2014-08-28 2016-03-03 Halozyme, Inc. Thérapie combinée associant une enzyme dégradant le hyaluronane et un inhibiteur des postes de contrôle immunitaire
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
PL3193952T3 (pl) * 2014-09-18 2019-09-30 Chondronest Sa Kompozycja zawierająca glikozaminoglikany i białka
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
US10793630B2 (en) 2014-12-04 2020-10-06 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
WO2016137471A1 (fr) * 2015-02-26 2016-09-01 Nantpharma, Llc Procédé pour améliorer la qualité de l'héparine
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
JP6827426B2 (ja) 2015-05-20 2021-02-10 ヤンセン バイオテツク，インコーポレーテツド 軽鎖アミロイドーシス及びその他のｃｄ３８陽性血液悪性疾患の治療のための抗ｃｄ３８抗体
KR102661078B1 (ko) 2015-05-29 2024-05-23 애브비 인코포레이티드 항-ｃｄ40 항체 및 그의 용도
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MX2018000265A (es) * 2015-06-22 2018-05-23 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina.
LT3313441T (lt) 2015-06-24 2024-05-27 Janssen Biotech, Inc. Imuniteto moduliavimas ir solidinių navikų gydymas antikūnais, kurie specifiškai suriša cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN116059340A (zh) 2015-09-11 2023-05-05 艾伯维公司 用于治疗复发形式的多发性硬化的方法
ES2862425T3 (es) 2015-11-03 2021-10-07 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SG11201803606XA (en) 2015-11-13 2018-05-30 Univ Massachusetts Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia
ITUB20159209A1 (it) * 2015-12-21 2017-06-21 Fidia Farm Spa Nanosistemi per il trasporto controllato di molecole attive a fini diagnostici, prognostici e terapeutici
US10493247B2 (en) 2016-03-15 2019-12-03 Medtronic Holding Company Sàrl Devices for delivering a chemical denervation agent and methods of use
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
AU2017238172B2 (en) 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20170349653A1 (en) 2016-06-01 2017-12-07 Abbvie Inc. Methods for treating spinal cord injury and pain
CA3027033A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-cd98 et conjugues anticorps-medicament
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
CA3027044A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-b7-h3 et conjugues anticorps-medicaments
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
JP2019526611A (ja) 2016-09-13 2019-09-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 非タンパク質クロストリジウム毒素組成物
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
ES2827012T3 (es) * 2016-11-17 2021-05-19 Vcn Biosciences Sl Uso de vectores virales oncolíticos en el tratamiento del retinoblastoma
WO2018094253A1 (fr) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Formulations de liposomes multivésiculaires à microparticules de complexe de méloxicam de zinc et leurs procédés de fabrication
CN108367075B (zh) 2016-11-23 2022-08-09 免疫方舟医药技术股份有限公司 4-1bb结合蛋白及其用途
KR20240010538A (ko) 2017-01-17 2024-01-23 제넨테크, 인크. 피하 her 2 항체 제형
US20210101980A1 (en) 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
WO2019075468A1 (fr) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Procédés de traitement de tumeur
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
WO2019090330A1 (fr) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur
WO2019133166A1 (fr) * 2017-12-29 2019-07-04 The Trustees Of Columbia University In The City Of New York Hyaluronidase pour la prévention, le traitement, la réduction et/ou la suppression de l'œdème cérébral et de la pression intracrânienne
JP2021517588A (ja) 2018-03-13 2021-07-26 フンダシオン・パラ・ラ・インベスティガシオン・ビオメディカ・デル・オスピタル・ウニベルシタリオ・ラ・パスＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｃｉｏｎ Ｂｉｏｍｅｄｉｃａ Ｄｅｌ Ｈｏｓｐｉｔａｌ Ｕｎｉｖｅｒｓｉｔａｒｉｏ Ｌａ Ｐａｚ 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (fr) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées
WO2019182745A1 (fr) 2018-03-19 2019-09-26 Bryn Pharma, LLC Formulations pour la pulvérisation d'épinéphrine
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2019195452A1 (fr) 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anticorps anti-cd27 et leurs utilisations
CA3162141A1 (fr) 2018-04-24 2019-10-31 Allergan, Inc. Traitements de la presbytie
WO2019222435A1 (fr) 2018-05-16 2019-11-21 Halozyme, Inc. Procédés de sélection de sujets pour une polythérapie anticancéreuse avec un ph20 soluble conjugué à un polymère
JOP20200292A1 (ar) 2018-05-16 2020-11-15 Stichting Vumc Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
AU2019276640A1 (en) * 2018-06-01 2021-01-21 Musc Foundation For Research Development Glycan analysis of proteins and cells
WO2020003210A1 (fr) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anticorps anti-l1cam et leurs utilisations
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
JP7204729B2 (ja) * 2018-07-25 2023-01-16 アルテオゼン インコーポレイテッド 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
US20210395392A1 (en) 2018-10-09 2021-12-23 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
US20200121588A1 (en) 2018-10-17 2020-04-23 Janssen Biotech, Inc. Method of Providing Subcutaneous Administration of Anti-CD38 Antibodies
KR20210081384A (ko) 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020092546A1 (fr) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration d'une hyaluronidase et d'un anticorps anti-c5 pour le traitement d'états associés au complément
TW202039849A (zh) 2018-11-13 2020-11-01 美商健生生物科技公司 在產生抗cd38抗體之期間微量金屬的控制
CN109679823B (zh) * 2018-11-19 2022-03-15 江苏汇先医药技术有限公司 一种用于生物分子、细胞或细菌的捕获材料及捕获筛
CN114126714A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
EP3785701A4 (fr) * 2019-03-25 2022-03-16 Alteogen, Inc. Composition pharmaceutique comprenant le variant ph20 de la hyaluronidase humaine et un médicament, pour injection sous-cutanée
WO2020198676A1 (fr) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Méthodes de traitement de tumeur
WO2020198672A1 (fr) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Méthodes de traitement de tumeur
EP3946605A1 (fr) 2019-04-05 2022-02-09 Tauc3 Biologics Limited Anticorps anti-tauc3 et leurs utilisations
SG11202111253WA (en) * 2019-05-07 2021-11-29 Genzyme Corp Methods for quantifying drug concentration in a prodrug composition
US20220241765A1 (en) * 2019-05-24 2022-08-04 Glytech, Inc. Novel artificial protein catalyst
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
AU2020353079A1 (en) 2019-09-25 2022-04-14 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
WO2021076792A1 (fr) * 2019-10-15 2021-04-22 Standard Of Care Corporation Compositions comprenant de l'hyaluronidase et/ou de la collagénase et/ou de la 4-méthylumbelliférone (4-mu) et procédés de traitement l'utilisant
WO2021092220A1 (fr) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle
WO2021092221A1 (fr) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
US20230039268A1 (en) 2019-12-09 2023-02-09 Genentech, Inc. Anti-pd-l1 antibody formulations
EP4084821A4 (fr) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Molécules multifonctionnelles se liant à cd33 et utilisations associées
WO2021165226A1 (fr) 2020-02-17 2021-08-26 Biotest Ag Administration sous-cutanée de facteur viii
KR20220157446A (ko) 2020-03-23 2022-11-29 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-ccr8 항체
CN111529685A (zh) * 2020-04-21 2020-08-14 厦门诺康得生物科技有限公司 抗呼吸道病毒感染的鼻腔喷雾制剂
WO2022005499A1 (fr) 2020-06-29 2022-01-06 Genentech, Inc. Association à dose fixe de pertuzumab et de trastuzumab
JP2023533813A (ja) 2020-07-14 2023-08-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 一定用量配合剤のアッセイ
IL299205A (en) * 2020-07-17 2023-02-01 Geron Corp Subcutaneous telomerase inhibitor preparations and methods of using them
KR102649603B1 (ko) * 2020-08-07 2024-03-21 (주)알테오젠 재조합 히알루로니다제의 생산 방법
WO2022046920A2 (fr) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Molécules multifonctionnelles se liant à la calréticuline et utilisations associées
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
US20230265188A1 (en) 2020-08-28 2023-08-24 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022087402A1 (fr) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Thérapie par antagoniste de lag-3 pour le cancer du poumon
CN112168838A (zh) * 2020-10-23 2021-01-05 中国科学院动物研究所 透明质酸及其盐的治疗用途
US20220133861A1 (en) * 2020-10-30 2022-05-05 Standard Of Care Corporation Hyaluronidase compositions and methods of using same to treat edema
UY39520A (es) 2020-11-17 2022-05-31 Janssen Sciences Ireland Unlimited Co Tratamiento o prevención de la infección por vih
KR20230110763A (ko) 2020-11-17 2023-07-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 질환 또는 장애의 치료 또는 예방
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
CA3196999A1 (fr) 2020-12-28 2022-07-07 Masano HUANG Methodes de traitement des tumeurs
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
CN114350639B (zh) * 2021-03-05 2023-06-02 华熙生物科技股份有限公司 一种密码子优化的透明质酸水解酶基因及其表达
WO2022212876A1 (fr) 2021-04-02 2022-10-06 The Regents Of The University Of California Anticorps dirigés contre un cdcp1 clivé et leurs utilisations
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CA3214757A1 (fr) 2021-04-08 2022-10-13 Andreas Loew Molecules multifonctionnelles se liant au tcr et leurs utilisations
US20220332822A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
WO2022251645A1 (fr) 2021-05-27 2022-12-01 Steiner Ventures Llc Composition d'hyaluronidase pour administration intraveineuse et son procédé d'utilisation
CN115671267A (zh) 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
IL310608A (en) 2021-08-02 2024-04-01 argenx BV Dosage forms for subcutaneous administration
WO2023011502A1 (fr) * 2021-08-02 2023-02-09 甘李药业股份有限公司 Formulation stable comprenant un anticorps anti-il-4r
CN118139636A (zh) 2021-09-14 2024-06-04 武田药品工业株式会社 使用透明质酸酶的经促进的浓缩抗体制剂的递送
CA3224890A1 (fr) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Therapie par antagoniste de lag-3 pour cancer hematologique
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023134613A1 (fr) * 2022-01-14 2023-07-20 天津键凯科技有限公司 Dérivé d'acide hyaluronique ou sel de celui-ci, son procédé de préparation et son application
WO2023147371A1 (fr) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Polythérapie pour carcinome hépatocellulaire
WO2023164638A1 (fr) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Polythérapie pour carcinome colorectal
WO2023168305A1 (fr) 2022-03-01 2023-09-07 Exuma Biotech Corp. Particules virales comprenant de l'hyaluronidase liée à une membrane
WO2023168404A1 (fr) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur
CN114634920B (zh) * 2022-03-24 2024-02-27 江南大学 一种产人源透明质酸酶ph20的重组毕赤酵母及其构建方法
WO2023196987A1 (fr) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur
WO2023203255A1 (fr) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Compositions lyophilisées
WO2023203258A1 (fr) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Compositions liquides
WO2023230473A1 (fr) 2022-05-24 2023-11-30 Bristol-Myers Squibb Company Anticorps se liant au ccr8 humain
WO2023235847A1 (fr) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
WO2024095173A1 (fr) 2022-11-02 2024-05-10 Janssen Biotech, Inc. Méthodes de traitement de cancers
CN116253809A (zh) * 2023-04-19 2023-06-13 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法
CN117887691A (zh) * 2023-12-27 2024-04-16 山东福瑞达医药集团有限公司 一种透明质酸酶融合蛋白、酵母工程菌及构建方法与应用

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US305500A (en) * 1884-09-23 Window-bead fastener
US172892A (en) * 1876-02-01 Improvement in restaurant check-boxes
US8309A (en) * 1851-08-26 Washing-machine
US53247A (en) * 1866-03-13 Improved process for disintegrating fibers
US345770A (en) * 1886-07-20 Halp to nathan s
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3639200A (en) * 1969-12-19 1972-02-01 Armin Elmendorf Textured wood panel
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS6033474B2 (ja) * 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
US4573994A (en) 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
EP0162007A1 (fr) * 1984-04-18 1985-11-21 Geriaco AG Préparation stable et conservable d'insuline pour le traitement de l'acné vulgaris
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4687610A (en) * 1986-04-30 1987-08-18 E. I. Du Pont De Neumours And Company Low crystallinity polyester yarn produced at ultra high spinning speeds
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0263417A1 (fr) 1986-09-30 1988-04-13 BIOCHEMIE Gesellschaft m.b.H. Utilisation d'hyaluronidase
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE69026306T2 (de) 1989-05-27 1996-10-17 Seikagaku Kogyo Co Ltd Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine.
DE3921528A1 (de) * 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5215899A (en) 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
CA2092323A1 (fr) 1990-10-01 1992-04-02 George Y. Wu Ciblage de virus et de cellules pour internalisation selective par les cellules
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
DE69232591T2 (de) * 1991-01-23 2002-08-22 Matsushita Electric Ind Co Ltd Wasser- und Ölabweisende adsorbierte Folie
AU668505B2 (en) 1991-03-18 1996-05-09 Scripps Research Institute, The Oligosaccharide enzyme substrates and inhibitors: methods and compositions
DK0584279T3 (da) 1991-05-14 2001-06-11 Immune Response Corp Inc Målrettet aflevering af gener, som koder for immunogene proteiner
ES2149774T3 (es) 1991-06-05 2000-11-16 Univ Connecticut Aportacion dirigida de genes que codifican proteinas secretoras.
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1993014188A1 (fr) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
US5496718A (en) * 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
KR100357839B1 (ko) * 1994-03-07 2003-08-02 더 다우 케미칼 캄파니 생체활성및/또는표적화된덴드리머콘쥬게이트
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
CN1103782C (zh) * 1994-03-31 2003-03-26 安姆根有限公司 单聚乙二醇化的mgdf多肽
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747027A (en) * 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP0856026A1 (fr) * 1995-10-19 1998-08-05 Receptagen Corporation Polyethylene glycols de longueur discrete
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US6828431B1 (en) * 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6784023B2 (en) * 1996-05-20 2004-08-31 Micron Technology, Inc. Method of fabrication of stacked semiconductor devices
CA2255891C (fr) 1996-05-24 2007-12-04 Angiotech Pharmaceuticals, Inc. Compositions et methodes pour traiter ou prevenir des maladies des voies corporelles
US5958750A (en) * 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US5665069A (en) * 1996-07-19 1997-09-09 Cumer; Patricia Lynn Pressure-directed peribulbar anesthesia delivery device
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6103525A (en) * 1996-10-17 2000-08-15 The Regents Of The University Of California Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase
US6123938A (en) 1996-10-17 2000-09-26 The Regents Of The University Of California Human urinary hyaluronidase
US6193963B1 (en) * 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
BR9809558A (pt) 1997-05-22 2000-07-04 Advanced Corneal Systems Inc Uso de hialuronidase na fabricação de um preparado oftálmico para liquefazer o humor vìtreo no tratamento de perturbações do olho
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
SE512633C2 (sv) * 1997-07-09 2000-04-17 Cecilia Johnsson Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2903899A (en) * 1998-03-12 1999-09-27 Shearwater Polymers Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU3032400A (en) 1998-12-23 2000-07-31 Friedrich-Schiller-Universitat Jena Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid
US6528797B1 (en) * 1999-04-16 2003-03-04 The Regents Of The University Of Michigan Method and system for determining depth distribution of radiation-emitting material located in a source medium and radiation detector system for use therein
DK1173198T3 (da) 1999-04-29 2004-04-13 Ista Pharmaceuticals Inc Anvendelse af en bestemt hyaluronidase til eliminering af ar på, uigennemsigtighed og uklarhed på hornhinden
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2005016455A2 (fr) 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Anticorps variables
US6461802B1 (en) * 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
ATE317868T1 (de) 1999-12-22 2006-03-15 Nektar Therapeutics Al Corp Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
ATE315082T1 (de) 2000-01-25 2006-02-15 Sidney Kimmel Cancer Ct Myeloider koloniestimulierungsfaktor und verwendungen davon
US20030212021A1 (en) 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
DE10013735A1 (de) * 2000-03-23 2001-10-11 Bakelite Ag Härter für Epoxidverbindungen, Verfahren zu ihrer Herstellung und Verwendung
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US6745776B2 (en) 2001-04-10 2004-06-08 David B. Soll Methods for reducing postoperative intraocular pressure
FR2827377B1 (fr) * 2001-07-13 2003-12-05 Poudres & Explosifs Ste Nale Dispositif d'allumage pour microcharges pyrotechniques
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2003040211A2 (fr) * 2001-11-07 2003-05-15 Nektar Therapeutics Al, Corporation Polymeres ramifies et conjugues associes
US7368108B2 (en) * 2001-11-28 2008-05-06 Neose Technologies, Inc. Glycopeptide remodeling using amidases
US7064110B2 (en) * 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
US7049483B1 (en) 2002-07-15 2006-05-23 Bruce Eric Hudkins Transgenic bioluminescent plants
US6682904B1 (en) * 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
KR20040040782A (ko) * 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
EP1636248A4 (fr) * 2002-12-16 2006-09-06 Halozyme Inc Glycoproteine de chondroitinase (chasegp) humaine, son procede de preparation et compositions pharmaceutiques comprenant ladite glycoproteine
US6969514B2 (en) 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
CA2517145C (fr) 2003-03-05 2017-08-01 Halozyme, Inc. Glycoproteine hyaluronidase soluble (shasegp), procede de fabrication et compositions pharmaceutiques contenant ladite proteine
WO2004099422A2 (fr) 2003-03-28 2004-11-18 The Scripps Research Institute Particules d'adenovirus avec infectivite accrue des cellules dendritiques et particules avec infectivite reduite des hepatocytes
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CA2522544A1 (fr) 2003-04-15 2004-10-28 Ista Pharmaceuticals, Inc. Procede d'isolation et de purification d'hyaluronidase ovine
EP2161268A1 (fr) * 2003-04-30 2010-03-10 Trine Pharmaceuticals, Inc. Composés de carbacéphème-ß-lactame pour le traitement d'infections bactériennes
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
WO2004110360A2 (fr) 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central
WO2005030927A2 (fr) 2003-09-23 2005-04-07 Uab Research Foundation Procedes et compositions pour le controle de l'inflammation in vivo
WO2005118799A1 (fr) 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Hyaluronidase ovine
KR20070057767A (ko) 2004-06-15 2007-06-07 앤드류 셴 천 인지질 조성물 및 이의 제조 및 사용 방법
US7572613B2 (en) 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP3912395B2 (ja) 2004-07-12 2007-05-09 セイコーエプソン株式会社 半導体集積回路、検査装置および半導体集積回路の検査方法
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US20060181032A1 (en) * 2005-02-11 2006-08-17 Riggs Robert A Hybrid gasket
WO2007047242A2 (fr) 2005-10-14 2007-04-26 Soll David B Solutions irrigantes pour chirurgie ophtalmique contenant de la hyaluronidase et procede permettant d'eviter l'augmentation de la pression intra-oculaire post-operatoire
WO2007059473A2 (fr) 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Procedes de production et de purification de vecteurs adenoviraux
US7763582B2 (en) 2006-02-21 2010-07-27 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
US20100158331A1 (en) 2006-08-22 2010-06-24 Jacobs James P System and method for determining absolute position using a multiple wavelength signal
WO2009001670A1 (fr) 2007-06-05 2008-12-31 Teijin Limited Composition de résine de polycarbonate
WO2009037566A2 (fr) 2007-06-19 2009-03-26 Uvarkina Tamara P Hyaluronidase et son procédé d'utilisation
US8956412B2 (en) 2007-06-22 2015-02-17 Axiomed, LLC Artificial disc
JP4931230B2 (ja) 2007-06-22 2012-05-16 新菱冷熱工業株式会社 クリーンルームの空調方法及び空調装置
US20080314349A1 (en) 2007-06-25 2008-12-25 Robert Bosch Gmbh Green start engine control systems and methods
WO2009001455A1 (fr) 2007-06-27 2008-12-31 Hitachi, Ltd. Dispositif d'affichage à plasma
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
JP5650546B2 (ja) 2008-03-06 2015-01-07 ハロザイム インコーポレイテッド 可溶性ヒアルロニダーゼの大規模生産
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
NZ588638A (en) 2008-04-14 2012-09-28 Halozyme Inc Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8315366B2 (en) * 2008-07-22 2012-11-20 Shoretel, Inc. Speaker identification and representation for a phone
WO2010077297A1 (fr) 2008-12-09 2010-07-08 Halozyme, Inc. Polypeptides ph20 solubles étendus et leurs applications
US20110229451A2 (en) 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2010138918A1 (fr) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase comme adjuvant pour augmenter le volume d'injection et la dispersion de vésicules membranaires synthétiques de grand diamètre contenant un agent thérapeutique
BR112012005890B1 (pt) 2009-09-17 2023-01-17 Takeda Pharmaceutical Company Limited Co-formulação estável de hialuronidase e imunoglobulina e métodos de utilização da mesma
MX348420B (es) 2010-07-20 2017-06-12 Halozyme Inc Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
CA2810668A1 (fr) 2010-09-08 2012-03-15 Halozyme, Inc. Procedes d'evaluation et d'identification ou d'evolution de proteines therapeutiques conditionnellement actives
ES2634669T3 (es) * 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
BR112013032265A2 (pt) * 2011-06-17 2016-12-20 Halozyme Inc métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
US20130011378A1 (en) * 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
CN103889446B (zh) 2011-10-18 2017-03-08 德国杰特贝林生物制品有限公司 硫酸化糖胺聚糖与透明质酸酶组合用于改善因子viii的生物利用度
EP2771028A2 (fr) * 2011-10-24 2014-09-03 Halozyme, Inc. Diagnostic compagnon pour le traitement avec un agent anti-hyaluronane et procédés d'utilisation dudit diagnostic
WO2013102144A2 (fr) 2011-12-30 2013-07-04 Halozyme, Inc. Variants du polypeptide ph20, formulations en contenant et leurs utilisations
WO2013151774A1 (fr) 2012-04-04 2013-10-10 Halozyme, Inc. Polythérapie par un agent anti-hyaluronane et un taxane ciblant une tumeur
CN105727267B (zh) 2016-02-05 2020-05-26 苏州康聚生物科技有限公司 一种重组人透明质酸酶冻干制剂及其制备方法和应用
JP7204729B2 (ja) 2018-07-25 2023-01-16 アルテオゼン インコーポレイテッド 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Also Published As

Publication number Publication date
BRPI0408116A (pt) 2006-03-01
SI2405015T1 (sl) 2016-04-29
PL2163643T3 (pl) 2015-06-30
HK1138885A1 (en) 2010-09-03
EP2177620B1 (fr) 2014-11-19
IL227867A0 (en) 2013-09-30
HK1165834A1 (zh) 2012-10-12
EP1603541A4 (fr) 2006-11-22
US20170246264A1 (en) 2017-08-31
PL1603541T5 (pl) 2013-06-28
EP1603541B1 (fr) 2009-11-11
MXPA05009429A (es) 2005-12-12
CY1109750T1 (el) 2014-09-10
EP2405015A2 (fr) 2012-01-11
DK2177620T3 (en) 2015-01-26
US7767429B2 (en) 2010-08-03
JP4464395B2 (ja) 2010-05-19
LU92780I9 (fr) 2024-05-13
HK1086746A1 (en) 2006-09-29
US20120251620A1 (en) 2012-10-04
SI2163643T1 (sl) 2015-03-31
KR20050118273A (ko) 2005-12-16
KR101233457B1 (ko) 2013-02-15
ES2335005T3 (es) 2010-03-18
CA2517145A1 (fr) 2004-09-16
US9677061B2 (en) 2017-06-13
EP1603541A2 (fr) 2005-12-14
EP2163643A1 (fr) 2010-03-17
EP2311973A1 (fr) 2011-04-20
CY2016024I1 (el) 2017-06-28
US8765685B2 (en) 2014-07-01
US9677062B2 (en) 2017-06-13
ATE448323T1 (de) 2009-11-15
IL170300A (en) 2016-06-30
US20040268425A1 (en) 2004-12-30
SI1603541T1 (sl) 2010-03-31
EP1603541B2 (fr) 2013-01-23
ZA200507978B (en) 2007-03-28
AU2009245838B2 (en) 2013-05-09
US8431124B2 (en) 2013-04-30
LU92780I2 (fr) 2015-09-21
US8202517B2 (en) 2012-06-19
SG2012041067A (en) 2014-08-28
CY2015033I1 (el) 2016-06-22
US10898551B2 (en) 2021-01-26
HUE027661T2 (en) 2016-10-28
CY2015033I2 (el) 2016-06-22
CN1942588A (zh) 2007-04-04
US20090214505A1 (en) 2009-08-27
US8450470B2 (en) 2013-05-28
JP5756785B2 (ja) 2015-07-29
ES2526536T3 (es) 2015-01-13
HUS1600031I1 (hu) 2016-08-29
KR101363658B1 (ko) 2014-02-14
EP2405015A3 (fr) 2012-03-07
US11723959B2 (en) 2023-08-15
NZ542873A (en) 2008-07-31
CY1117358T1 (el) 2017-04-26
ES2564103T3 (es) 2016-03-17
EP3009517A1 (fr) 2016-04-20
US20140199282A1 (en) 2014-07-17
DK1603541T3 (da) 2010-03-29
AU2004218354A1 (en) 2004-09-16
WO2004078140A3 (fr) 2005-11-17
US20130058893A1 (en) 2013-03-07
KR20130135986A (ko) 2013-12-11
JP2010029190A (ja) 2010-02-12
SG177008A1 (en) 2012-01-30
PL2177620T3 (pl) 2015-05-29
DK2163643T3 (en) 2015-03-23
JP2013031446A (ja) 2013-02-14
CN102943067B (zh) 2016-06-22
EP2163643B1 (fr) 2015-01-21
US20090253175A1 (en) 2009-10-08
US8431380B2 (en) 2013-04-30
PT2163643E (pt) 2015-05-18
DK1603541T4 (da) 2013-04-15
IL227867A (en) 2015-09-24
JP5538770B2 (ja) 2014-07-02
CY1116110T1 (el) 2017-02-08
PL2405015T3 (pl) 2016-09-30
PT1603541E (pt) 2010-02-19
BRPI0408116B1 (pt) 2022-09-20
HK1138883A1 (en) 2010-09-03
DE602004024041D1 (de) 2009-12-24
CY1116370T1 (el) 2016-06-22
AU2009245838A1 (en) 2010-01-07
SI2177620T1 (sl) 2015-02-27
EP2177620A1 (fr) 2010-04-21
JP2006524507A (ja) 2006-11-02
US20110152359A1 (en) 2011-06-23
EA200501384A1 (ru) 2006-06-30
ES2532399T3 (es) 2015-03-26
CN1942588B (zh) 2013-06-12
EP2330213A1 (fr) 2011-06-08
ES2335005T5 (es) 2013-04-17
AU2004218354B2 (en) 2009-10-01
US8772246B2 (en) 2014-07-08
EA009383B1 (ru) 2007-12-28
EP2405015B1 (fr) 2016-01-06
US9562223B2 (en) 2017-02-07
CA2517145C (fr) 2017-08-01
WO2004078140A2 (fr) 2004-09-16
US20120148555A1 (en) 2012-06-14
US20190224286A1 (en) 2019-07-25
CN102943067A (zh) 2013-02-27
DK2405015T3 (en) 2016-03-21
PT2177620E (pt) 2015-02-16
US10286044B2 (en) 2019-05-14
US20090181013A1 (en) 2009-07-16
FR16C0030I1 (fr) 2016-08-26
US20210023184A1 (en) 2021-01-28
SI1603541T2 (sl) 2013-04-30
US20090181032A1 (en) 2009-07-16
KR20110114692A (ko) 2011-10-19
US20230321203A1 (en) 2023-10-12
KR20120094493A (ko) 2012-08-24
CY2016024I2 (el) 2017-06-28
PL1603541T3 (pl) 2010-04-30

Similar Documents

Publication Publication Date Title
LU93138I2 (fr) Glycoprotéine d'hyaluronidase soluble (shasegp), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant
SG164386A1 (en) Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004058147A3 (fr) Glycoproteine de chondroitinase (chasegp) humaine, son procede de preparation et compositions pharmaceutiques comprenant ladite glycoproteine
AU7617796A (en) Variants of human recombinant interferon-gamma (rhu-ifn-gamma) having increased heat-stability
NO20031159D0 (no) Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner
WO2002044197A3 (fr) Peptides de fixation des recepteurs des cytokines
WO2000063415A8 (fr) Adn codant le recepteur humain des vanilloides vr1
WO2001083722A3 (fr) Enzymes therapeutiques, et methodes de traitement du mps-vi et de lignees de cellules en vue de l'obtention de ces enzymes par recombinaison
NO301805B1 (no) Fremgangsmåte for fremstilling av et stabilt, galenisk, vandig preparat av erytropoietin